Vertex Pharmaceuticals Incorporated
VRTX
$489.10
$3.210.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.67% | 129.09% | -426.81% | 13.50% | -6.42% |
| Total Depreciation and Amortization | -59.96% | -1.48% | 0.93% | 13.35% | 12.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.97% | 314.96% | 13.22% | -47.05% | 2,076.19% |
| Change in Net Operating Assets | -455.68% | 165.24% | -286.70% | 115.41% | -544.10% |
| Cash from Operations | -57.32% | 136.49% | -387.28% | 456.95% | -81.50% |
| Capital Expenditure | -36.78% | 1.88% | -0.88% | -17.73% | -43.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -160.19% | 28.98% | 80.91% | -149.64% | -974.45% |
| Cash from Investing | -136.18% | 24.95% | 78.30% | -140.99% | -653.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 75.93% | 60.58% | -3.79% | -10.00% | -6.19% |
| Issuance of Common Stock | 308.33% | -84.73% | 225.44% | -63.58% | 201.30% |
| Repurchase of Common Stock | -8.64% | 2.35% | -9.90% | -138.83% | 10.28% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | -74.29% | 333.33% | -236.36% |
| Cash from Financing | -0.98% | -8.06% | -0.31% | -198.41% | 27.39% |
| Foreign Exchange rate Adjustments | -307.46% | 1,012.00% | 83.97% | -156.93% | 221.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.86% | 114.35% | -280.61% | -61.61% | -177.27% |